

Intraoperative Dexmedetomidine Use On Adult Surgical GONZAGA Patients at Providence Sacred Heart Medical Center

Christina Rose, BSN, RN; Scot Pettey, DNAP, CRNA; Norel Smith, CRNA; Kenn B. Daratha, PhD Providence Sacred Heart Medical Center & Gonzaga University School of Anesthesia

Background

Opioids are considered the standard of practice for intraoperative and postoperative pain management but yield unfavorable outcomes.⁶ The research evidence demonstrates reductions in post-operative opioid use following intraoperative administration of dexmedetomidine.^{1,3,4,5,6} Due to the prospective nature of literature surrounding dexmedetomidine, the rate of implementation remains largely unknown.

The aim of this retrospective, observational project was to identify the rate of adoption of intraoperative dexmedetomidine administration among adult surgical patients at Providence Sacred Heart Medical Center (PSHMC) from January 1, 2015 to December 31, 2019. Accordingly, investigation into dexmedetomidine administration at PSHMC may shed light on this strategy aimed to minimize opioid exposure

Methods

- Retrospective, observational evidence-based practice project.
- Approved by the PSHMC Clinical Innovation and Research Council and deemed exempt from human subject's research by Providence Health Care Institutional Review Board.
- Data extracted, de-identified and stored in HIPPA compliant Redcap project database.
- Included adults over the age of 18 years, undergoing surgical procedure from January 1, 2015 to December 31, 2019.
- Excluded pediatric patients less than 18 years of age, intranasal dexmedetomidine administration, patients undergoing outpatient procedures not admitted to the hospital, hospital length of stay less than 24 hours and greater than 14 days, and morphine equivalent dosing exceeding 200 milligrams.
- Univariate and bivariate analyses examined baseline group comparability, occurrence of intraoperative dexmedetomidine administration.
- Multivariable analysis examined independent risk factors associated with receiving intraoperative dexmedetomidine.

S

Findings

Table 1. Comparison of Baseline Demographics and Characteristics (N=26,990)				Figure 1. Percentage of Cases Receiving Intraoperative Dexmedetomidine and Opioids at PSHMC					
haracteristics	Values	Count	Percent	100 00%		96.30%			
exmedetomidine		668	2.5%						
ender	Female	13,605	50.4%	80.00%					
	Males	13,385	49.6%	60.00%					
SA	1	614	2.3%						
	2	8,005	29.7%	40.00%					
	3	13,097	48.5%	20.00%					
	4	3,507	13.0%					2 50%	
istory	Backpain	5,716	21.2%	0.00%				2.3070	
	Chronic Pain	1,823	6.8%		(Opioids (Y)	De	xmedetomic	line (Y)
	Opioid Treatment	226	0.8%			• • • •			
	Opioid Administration	25,993	96.3%	Figure 2. Intraoperative Dexmedetomidine Administration					
ervice Lines	Neurosurgery	3,040	11.3%			Annual Tren	ds at PSH	MC	
	Cardiothoracic	4,580	17.0%	8.00%					
	ENT	685	2.5%	6.00% 4.00% 2.00%					
	Orthopedics	6,554	24.3%						
	General	5,121	19.0%						
	Vascular	1,737	6.4%						
	IR	551	2.0%						
	Plastics	906	3.4%	0.00%					
	Gastroenterology	681	2.5%		2015 (0.5%)	2016 20 ⁷ (0.7%) (1.5	2017	2018 (2.4%)	2019 (6.9%)
	Urology	1,296	4.8%				2017 (1 5%)		
ase Type	Elective	18,331	67.9%				1.570		
	Emergent	602	2.2%						
	Urgent	7,606	28.2%	Table 2. Independent Risk Factors on Intraoperative Dexmedetomidine Administration at PSHMC					
haracteristic		Mean	SD	Variable					
ge (years)		62	16						
MI (kg/m2)		29.7	40	Back Pai	n		0.92	0.85-1.26	<0.001
				ENT, Max	illofacial, c	or Oral Surgery	6.15	4.60-8.23	<0.001
		Median		Cardiothoracic or Cardiovascular Neurosurgery Opioid Treatment			3.64	2.93-4.54	<0.001
ase Duration (minutes)		166	111-276				3 22	2 55-4 07	<0.001
hase 1 Duration (minutes) ength of Stay (minutes)		69	52-94				2.22 2 QA	1 52 5 11	
		6,142	4,166-9,302				∠.00	1.55-5.14	<0.001
SA: American Societ	y of Anesthesiology Physica	Classification:	Dex: dexmedetomidine:	Opioid A	dministrati	on	0.54	0.36-0.81	<0.001
D: standard deviation	n; IQR: interquartile range; I	_OS: Length of S	tay; IR: Interventional	24-Hour l	Morphine E	quivalent Dosi	ng 1.00	1.00-1.00	0.035

Radiology



Intraoperative dexmedetomidine is an effective evidencedbased strategy to promote opioid sparing effect and reduce 24hour opioid consumption.^{1,4,5,6} Findings identified a 2.5% occurrence of intraoperative dexmedetomidine and 96.3% opioid occurrence in adult surgical patients at (PSHMC) from January 1, 2015 to December 31, 2019. The occurrence of dexmedetomidine administration is not a widespread practice used at PSHMC, but its utilization is increasing. History of backpain and intraoperative opioid administration were independently associated with decreased intraoperative dexmedetomidine use. ENT, maxillofacial and oral surgery were the greatest risk factors for intraoperative dexmedetomidine administration. History of home opioid treatment was also associated with increased intraoperative dexmedetomidine use. The research evidence demonstrates that intraoperative dexmedetomidine is a promising new avenue to reduce postoperative opioid use.^{3,4,5,6} The purpose of this retrospective, observational project serves as a foundation for additional examination to identify and report interventions to reduce opioid administration and improve quality initiatives surrounding multimodal analgesia.

. Bielka, K., Kuchyn, I., Babych, V., Martycshenko, K., & Inozemtsev, O. (2018). Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic cholecystectomy: a randomized controlled study. BMC Anesthesiology, 18(1).

2. Hah, J., Bateman, B., Ratliff, J., Curtin, C., & Sun, E. (2017). Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic. doi: 10.1213/ANE.000000000002458

3. Grape, S., Kirkham, K. R., Frauenknecht, J., & Albrecht, E. (2019). Intra-operative analgesia with remifentanil vs. . dexmedetomidine: a systematic review and meta-analysis with trial sequential analysis. 793–800.

4. Singh, P. M., Panwar, R., Borle, A., Mulier, J. P., Sinha, A., & Goudra, B. (2017). Perioperative analgesic profile of dexmedetomidine infusions in morbidly obese undergoing bariatric surgery: a meta-analysis and trial sequential analysis. Surgery for Obesity and Related Diseases, 13(8), 1434–1446.

5. Schnabel, A., Meyer- Frieem, C. H., Reichl, S. U., Zahn, P. K., & Pogatzki-Zahn, E. M. (2013). Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A metaanalysis of randomized controlled trials. Pain, 154(7), 1140-1149.

6. Koepke, E. J., Manning, E. L., Miller, T. E., Ganesh, A., Williams, D. G. A., & Manning, M. W. (2018). The rising tide of opioid use and abuse: the role of the anesthesiologist. *Perioperative Medicine*, 7(1). doi: 10.1186/s13741-018-0097-4

School of Nursing & Human Physiology

Discussion

References